Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists
- PMID: 33463043
- DOI: 10.1111/dom.14173
Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists
Abstract
Aim: The aim of this study was to evaluate amino acids as glucagon receptor (GCGR)-specific biomarkers in rodents and cynomolgus monkeys in the presence of agonism of both glucagon-like peptide-1 receptor (GLP1R) and GCGR with a variety of dual agonist compounds.
Materials and methods: Primary hepatocytes, rodents (normal, diet-induced obese and GLP1R knockout) and cynomolgus monkeys were treated with insulin (hepatocytes only), glucagon (hepatocytes and cynomolgus monkeys), the GLP1R agonist, dulaglutide, or a variety of dual agonists with varying GCGR potencies.
Results: A long-acting dual agonist, Compound 2, significantly decreased amino acids in both wild-type and GLP1R knockout mice in the absence of changes in food intake, body weight, glucose or insulin, and increased expression of hepatic amino acid transporters. Dulaglutide, or a variant of Compound 2 lacking GCGR agonism, had no effect on amino acids. A third variant with ~31-fold less GCGR potency than Compound 2 significantly decreased amino acids, albeit to a significantly lesser extent than Compound 2. Dulaglutide (with saline infusion) had no effect on amino acids, but an infusion of glucagon dose-dependently decreased amino acids on the background of GLP1R engagement (dulaglutide) in cynomolgus monkeys, as did Compound 2.
Conclusions: These results show that amino acids are sensitive and translatable GCGR-specific biomarkers.
Keywords: amino acids, glucagon receptor, glucagon‐like peptide‐1 receptor, oxyntomodulin, pharmacology.
© 2020 John Wiley & Sons Ltd.
Similar articles
-
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.Diabetes. 2009 Oct;58(10):2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14. Diabetes. 2009. PMID: 19602537 Free PMC article.
-
The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.Obesity (Silver Spring). 2012 Aug;20(8):1566-71. doi: 10.1038/oby.2012.67. Epub 2012 Mar 16. Obesity (Silver Spring). 2012. PMID: 22421924 Free PMC article.
-
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.Biopolymers. 2012;98(5):443-50. doi: 10.1002/bip.22072. Biopolymers. 2012. PMID: 23203689
-
Unraveling oxyntomodulin, GLP1's enigmatic brother.J Endocrinol. 2012 Dec;215(3):335-46. doi: 10.1530/JOE-12-0368. Epub 2012 Sep 27. J Endocrinol. 2012. PMID: 23019069 Free PMC article. Review.
-
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy.Peptides. 2023 Apr;162:170962. doi: 10.1016/j.peptides.2023.170962. Epub 2023 Feb 2. Peptides. 2023. PMID: 36736539 Review.
Cited by
-
Mounting clues suggest the coronavirus might trigger diabetes.Nature. 2020 Jul;583(7814):16-17. doi: 10.1038/d41586-020-01891-8. Nature. 2020. PMID: 32606460 No abstract available.
-
New-Onset Diabetes in COVID-19: Time to Frame Its Fearful Symmetry.Diabetes Ther. 2021 Feb;12(2):461-464. doi: 10.1007/s13300-020-00988-7. Epub 2020 Dec 26. Diabetes Ther. 2021. PMID: 33367980 Free PMC article.
-
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.Diabetologia. 2024 Mar;67(3):470-482. doi: 10.1007/s00125-023-06053-9. Epub 2023 Dec 14. Diabetologia. 2024. PMID: 38095657 Free PMC article. Clinical Trial.
-
Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients.Clin Exp Med. 2023 Feb;23(1):141-150. doi: 10.1007/s10238-022-00795-3. Epub 2022 Jan 22. Clin Exp Med. 2023. PMID: 35066730 Free PMC article.
-
Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk.Diabetes. 2025 Jun 1;74(6):885-897. doi: 10.2337/db24-0958. Diabetes. 2025. PMID: 40095004 Free PMC article.
References
REFERENCES
-
- Shankar SS, Shankar RR, Mixson LA, et al. Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes. Diabetes. 2018;67:1105‐1112.
-
- Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88:4696‐4701.
-
- Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsboll T. Effect of oxyntomodulin, glucagon, GLP‐1, and combined glucagon +GLP‐1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab. 2015;100:4541‐4552.
-
- Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double‐blind, randomized, controlled trial. Diabetes. 2005;54:2390‐2395.
-
- Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006;30:1729‐1736.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources